{"id":51072,"date":"2022-11-21T14:02:02","date_gmt":"2022-11-21T13:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/"},"modified":"2022-11-21T14:02:02","modified_gmt":"2022-11-21T13:02:02","slug":"pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/","title":{"rendered":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc.<\/a> (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nPear will be available for one-on-one meetings during the conference. Investors interested in meeting with Pear at the conference should contact their Evercore representative.\n<\/p>\n

\nA live audio webcast of the presentation can be accessed by clicking here<\/a> and will be made available in the Investors section of Pear\u2019s website at www.peartherapeutics.com<\/a>. A replay of the webcast will be available on Pear\u2019s website for up to 30 days following the live presentation.\n<\/p>\n

\nAbout Pear Therapeutics<\/b>\n<\/p>\n

\nPear Therapeutics, Inc., which is traded on Nasdaq as PEAR, is the parent company of Pear Therapeutics (US), Inc. Pear is the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs). Pear aims to redefine care through the widespread use of clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has the first end-to-end platform to discover, develop, and deliver PDTs to patients and a pipeline of products and product candidates across therapeutic areas., including the first three PDTs with disease treatment claims from the FDA. Pear\u2019s product, reSET\u00ae, for the treatment of substance use disorder, was the first PDT to receive marketing authorization from the FDA to treat disease. Pear\u2019s second product, reSET-O\u00ae, for the treatment of opioid use disorder, was the first PDT to receive Breakthrough Designation. Pear\u2019s third product, Somryst\u00ae for the treatment of chronic insomnia, was the first PDT submitted through FDA\u2019s traditional 510(k) pathway while simultaneously reviewed through FDA\u2019s Software Precertification Pilot Program. For more information, visit Pear at www.peartherapeutics.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investors:<\/b>
Meara Murphy
\n
Senior Director, Corporate Communications
\n
meara.murphy@peartherapeutics.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-51072","6":"format-standard","7":"category-industry"},"yoast_head":"\nPear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-21T13:02:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference\",\"datePublished\":\"2022-11-21T13:02:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/\"},\"wordCount\":349,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005020\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/\",\"name\":\"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005020\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"datePublished\":\"2022-11-21T13:02:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005020\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221121005020\\\/en\\\/754943\\\/21\\\/Logo-Pear-Therapeutics-Final.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the Evercore ISI 5th Annual HealthCONx Conference on Wednesday, November 30, 2022. Corey McCann, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at 12:10 p.m. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-21T13:02:02+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference","datePublished":"2022-11-21T13:02:02+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/"},"wordCount":349,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/","url":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/","name":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","datePublished":"2022-11-21T13:02:02+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221121005020\/en\/754943\/21\/Logo-Pear-Therapeutics-Final.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/pear-therapeutics-to-participate-in-evercore-isi-5th-annual-healthconx-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Pear Therapeutics to Participate in Evercore ISI 5th Annual HealthCONx Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=51072"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/51072\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=51072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=51072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=51072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}